Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ3 | P48549 | 14/20 | 0.43 |
| ▸ | KCNJ6 | P48051 | 13/20 | 0.43 |
| ▸ | KCNJ5 | P48544 | 11/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9681843 | 0.98 | KCNJ3 (0.42) | KCNJ3KCNJ6KCNJ5HCAR3TSHR | |
| SCHEMBL25400204 | 0.97 | KCNJ3 (0.45) | KCNJ3KCNJ6KCNJ5HCAR3 | |
| SCHEMBL287415 | 0.93 | NOTUM (0.41) | KCNJ3KCNJ6KCNJ5HCAR3TSHR | |
| SCHEMBL22637656 | 0.86 | KCNJ6 (0.46) | KCNJ3KCNJ6KCNJ5TSHR | |
| SCHEMBL9681838 | 0.85 | KCNJ6 (0.40) | KCNJ3KCNJ6KCNJ5 | |
| SCHEMBL3060712 | 0.82 | KCNJ6 (0.42) | KCNJ3KCNJ6KCNJ5 | |
| SCHEMBL9681221 | 0.80 | KMT2A (0.44) | KCNJ3KCNJ6KCNJ5TSHR | |
| SCHEMBL25399863 | 0.77 | KMT2A (0.46) | KCNJ3KCNJ6KCNJ5TSHR | |
| SCHEMBL16344633 | 0.76 | KMT2A (0.48) | KCNJ3KCNJ6KCNJ5TSHR | |
| SCHEMBL26271961 | 0.75 | KDM4E (0.42) | KCNJ3KCNJ6KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-5126362-A | Substituted pyrazoylacetamides | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0361362-A1 | Oxime derivative and fungicide for agricultural and horticultural use | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535633-B2 | Fused tricyclic heterocycle compounds and therapeutic uses thereof | STING1, CGAS, MAVS | KCNJ3 2371/4885KCNJ6 2281/4885KCNJ5 2326/4885 |
| US-20210300944-A1 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF | STING1, CGAS, MAVS | KCNJ3 2371/4885KCNJ6 2281/4885KCNJ5 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.